Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scalp cancer surgery that leaves hair follicles behind

NCT ID NCT07809191

Symptom relief Sponsor: The Cooper Health System Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers are testing a modified surgical technique for squamous cell carcinoma in situ on the scalp, an early form of skin cancer. Standard surgery can remove deep tissue that holds hair follicles, causing permanent bald spots. This pilot study uses partial thickness excision, which removes only the top layers of skin, to see whether the cancer clears and hair grows back. About 15 adults with confirmed scalp lesions join, and doctors track hair density and cancer clearance over six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
partial thickness excision, a shallower surgical removal of the top skin layers
What this could lead to
If it works, this technique could let surgeons treat early scalp skin cancer while sparing the hair follicles underneath, so patients avoid a permanent bald patch.
What could go wrong
This is a small pilot study of 15 people, so it cannot prove the approach works for everyone. Shallower surgery may leave cancer cells behind, and hair regrowth varies from person to person.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults ≥ 18 years old * Histologically confirmed SCCIS * Lesions located in the hair-bearing scalp * Ability to provide informed consent Exclusion Criteria: * Invasive, poorly differentiated, or high-risk SCC features (e.g., perineural invasion) * Recurrent SCC at the same site * Prior radiation therapy to the scalp * Scarring alopecia or active inflammatory scalp disease at the treatment site * Immunosuppression that, in the investigator's judgement, increases oncologic risk * Use of topical minoxidil, oral minoxidil, finasteride, spironolactone, or other hair-growth promoting agents

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia skin squamous cell carcinoma in situ squamous carcinoma in situ squamous cell carcinoma Squamous Intraepithelial Lesions

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia Squamous cell carcinoma (skin) Squamous cell carcinoma in situ

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.